Holen Sie sich die Stockscreener-App
0.1121
3.80%
0.0041
Vorhandelsmarkt:
.12
0.0079
+7.05%
Schlusskurs vom Vortag:
$0.108
Offen:
$0.1082
24-Stunden-Volumen:
2.10M
Relative Volume:
0.30
Marktkapitalisierung:
$104.20M
Einnahmen:
$420.00K
Nettoeinkommen (Verlust:
$-26.98M
KGV:
-0.0269
EPS:
-4.1721
Netto-Cashflow:
$-32.01M
1W Leistung:
-2.10%
1M Leistung:
-34.14%
6M Leistung:
-85.29%
1J Leistung:
-96.91%
1-Tages-Spanne:
$0.1082
$0.1175
1-Wochen-Bereich:
$0.103
$0.1179
52-Wochen-Spanne:
$0.1022
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1121 | 104.20M | 420.00K | -26.98M | -32.01M | -4.1721 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Eingeleitet | Mizuho | Outperform |
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Kala Bio chases 'Palantir for biotech' dream with new AI platform - MSN
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Kala Bio rises on plans to leverage AI - MSN
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened - MSN
KALA Stock Price, Quote & Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
KALA BIO (KALA) Stock Volatility | Q3 2025: EPS Tops ViewsElite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine - ADVFN
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
KALA BIO (KALA) Stock Shared Voting (Momentum Fading) 2026-04-20Gap Up Stocks - Xã Thanh Hà
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused - openPR.com
Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA) - PRLog
Kala Bio Transitions to AI-Powered Biotech Solutions with Researgency Platform and MSC-S Asset Strategy 47 - Minichart
KALA BIO (NASDAQ:KALA) Posts Quarterly Earnings Results - MarketBeat
KALA BIO: Q4 Earnings Snapshot - Barchart
Eye-drug setback pushes KALA BIO (NASDAQ: KALA) toward high-risk AI bet - Stock Titan
KALA BIO, Inc. (NASDAQ:KALA) Sees Significant Drop in Short Interest - MarketBeat
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
What is the bull case for KALA BIO (KALA) Stock | Price at $0.18, Up 0.17%Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Earnings Risk: What is KALA BIO Incs market position2026 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
What do insiders think about KALA BIO (KALA) Stock | Price at $0.17, Up 5.70%Fundamentals - Xã Vĩnh Công
Is KALA BIO (KALA) Stock Showing Strength | Price at $0.17, Up 2.70%Real Trader Insights - Xã Vĩnh Công
Kala Pharmaceuticals Inc (27F0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
KALA Bio launches on-premises AI platform for biotech sector By Investing.com - Investing.com India
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio engages advisor to review clinical assets, AI analytics By Investing.com - Investing.com South Africa
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio Delays 2025 Annual Report Filing - The Globe and Mail
KALA BIO, Inc. (KALA) stock price, news, quote and history - Yahoo Finance UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - manilatimes.net
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ... - Caledonian Record
KALA Stock Analysis: KALA BIO Inc. Drops 5.83% to $0.16, Biotech Performance Review - UBND thành phố Hải Phòng
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Bionic Intelligence Research Agent Now Commercially Live - openPR.com
User - The Chronicle-Journal
Kala Bio deploys AI research agent for biotech clients By Investing.com - Investing.com South Africa
Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent - marketscreener.com
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Kala Bio deploys AI research agent for biotech clients - Investing.com
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - The Manila Times
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):